Journal article
A phase II trial of 5‐fluorouracil, doxorubicin, mitomycin C, and leucovorin in advanced gastric carcinoma
Cancer, Vol.65(11), pp.2442-2445
06/01/1990
DOI: 10.1002/1097-0142(19900601)65:11<2442::AID-CNCR2820651106>3.0.CO;2-7
PMID: 2337858
Abstract
To determine the feasibility and toxicity of combining leucovorin (CF) with a 5‐fluorouracil (5‐FU) combination chemotherapy regimen currently accepted by many as standard treatment for gastric cancer, CF (500 mg/m2) was administered in combination with the Georgetown 5‐FU, doxorubicin, and mitomycin C (FAM) regimen. Thirty‐two patients with advanced adenocarcinoma of the stomach were evaluable for toxicity and 26 patients with measurable disease were evaluable for response. Fifty‐four percent of patients were previously treated with chemotherapy or radiation therapy. The response rate was 38% (95% confidence interval, 21% to 59%). The median duration of response was 6 months (range, 2 to 23+ months). The estimated median survival time was 6.8 months for patients with measurable disease and 11.5 months for all 32 patients. Although diarrhea is dose limiting when 5‐FU and CF are administered weekly for 6 of 8 weeks, diarrhea occured rarely on this combination regimen with 5‐FU and CF administered only 4 of every 8 weeks. The dose‐limiting toxicity of FAM‐CF was cumulative myelosuppression, which also occurs with the standard FAM regimen. As a result, the administered dose intensity of 5‐FU decreased as patients continued on study. Thus, a randomized comparison of FAM with FAM‐CF would not determine whether CF modulation increases the efficacy of 5‐FU when it is administered in optimal doses to patients with gastric cancer.
Details
- Title: Subtitle
- A phase II trial of 5‐fluorouracil, doxorubicin, mitomycin C, and leucovorin in advanced gastric carcinoma
- Creators
- Susan G. Arbuck - Roswell Park Cancer InstituteYusuf Silk MdHarold O. Douglass - Roswell Park Cancer InstituteHector Nava - Roswell Park Cancer InstituteYoucef M. Rustum - Roswell Park Cancer InstituteSuzanne Milliron - Roswell Park Cancer Institute
- Resource Type
- Journal article
- Publication Details
- Cancer, Vol.65(11), pp.2442-2445
- Publisher
- Wiley Subscription Services, Inc., A Wiley Company
- DOI
- 10.1002/1097-0142(19900601)65:11<2442::AID-CNCR2820651106>3.0.CO;2-7
- PMID
- 2337858
- ISSN
- 0008-543X
- eISSN
- 1097-0142
- Number of pages
- 4
- Grant note
- National Cancer Institute (CA21071)
- Language
- English
- Date published
- 06/01/1990
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359581802771
Metrics
22 Record Views